Trials / Terminated
TerminatedNCT00073450
Study of Lonafarnib in Patients With Recurrent Squamous Cell Carcinoma of the Head and Neck (Study P02530)
An Open-Label Phase 2 Study of Lonafarnib in Patients With Recurrent Squamous Cell Carcinoma of the Head and Neck
- Status
- Terminated
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 15 (actual)
- Sponsor
- Merck Sharp & Dohme LLC · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to determine the safety and efficacy of an oral Farnesyl Protein Transferase Inhibitor (Lonafarnib/SCH 6636) as a single agent in Adult Patients With Squamous Cell Carcinoma of the Head \& Neck and will help determine if further development is justified.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Farnesyl Protein Transferase Inhibitor |
Timeline
- Start date
- 2003-09-01
- Primary completion
- 2004-06-01
- Completion
- 2004-06-01
- First posted
- 2003-11-24
- Last updated
- 2015-04-21
Source: ClinicalTrials.gov record NCT00073450. Inclusion in this directory is not an endorsement.